NEW YORK ( TheStreet) -- Myriad Genetics (Nasdaq: MYGN) hit a new 52-week high Friday as it is currently trading at $25.74, above its previous 52-week high of $25.45 with 237,097 shares traded as of 9:48 a.m. ET. Average volume has been 812,200 shares over the past 30 days. Myriad has a market cap of $2.1 billion and is part of the services sector and diversified services industry. Shares are up 11.1% year to date as of the close of trading on Thursday. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of novel predictive medicine, personalized medicine, and prognostic medicine products. The company has a P/E ratio of 18.6, above the average diversified services industry P/E ratio of 18.4 and above the S&P 500 P/E ratio of 17.7.
- Practice your MYGN trading strategies and win cash in our stock game.